United States - English - NLM (National Library of Medicine)

janssen pharmaceutical, inc. - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - risperidone is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperidone is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] . adjunctive therapy risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperidone is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing

United States - English - NLM (National Library of Medicine)

cardinal health - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - risperidone is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperidone is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] . adjunctive therapy risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperidone is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 2 mg - risperidone (risperidone) is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies ( 14.1) ]. monotherapy risperidone is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies ( 14.2) ]. adjunctive therapy risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies ( 14.3) ]. pediatrics risperidone is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.5 mg - risperidone (risperidone) is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies ( 14.1) ]. monotherapy risperidone is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies ( 14.2) ]. adjunctive therapy risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies ( 14.3) ]. pediatrics risperidone is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 2 mg - risperidone tablets are indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperidone tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] .  adjunctive therapy risperidone tablets adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperidone tablets are indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness,

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg - risperidone tablets are indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperidone tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years)[see clinical studies (14.2)] .  adjunctive therapy risperidone tablets adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperidone tablets are indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, tem

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg in 1 ml - adults risperidone is indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1)] . adolescents risperidone is indicated for the treatment of schizophrenia in adolescents aged 13 - 17 years [see clinical studies (14.1)] . monotherapy - adults and pediatrics risperidone is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults and in children and adolescents aged 10 - 17 years [see clinical studies (14.2)] . combination therapy – adults the combination of risperidone with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder [see clinical studies (14.3)] . pediatrics risperidone is indicated for the treatment of irritability associated with autistic disorder in children and adolescents aged 5–16 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods [see clinical

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 2 mg - adults risperidone (risperidone) is indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1)]. adolescents risperidone is indicated for the treatment of schizophrenia in adolescents aged 13–17 years [see clinical studies (14.1)]. monotherapy adults and pediatrics risperidone is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults and in children and adolescents aged 10-17 years [see clinical studies (14.2)]. combination therapy adults the combination of risperidone with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder [see clinical studies (14.3)]. pediatrics risperidone is indicated for the treatment of irritability associated with autistic disorder in children and adolescents aged 5–16 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods [see clinic

United States - English - NLM (National Library of Medicine)

ratiopharm inc - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone .25 mg - adults risperidone tablets are  indicated  for  the  acute  and  maintenance  treatment  of schizophrenia [see clinical studies (14.1)] . adolescents due to janssen pharmaceuticals corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia. pediatric use information  for the treatment of pediatric patients with schizophrenia, 13 to 17 years of age, is approved for janssen pharmaceuticals corporation’s risperidone drug products. monotherapy - adults risperidone tablets are indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults [see clinical studies (14.2)] . due to janssen pharmaceuticals corporation’s marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with bipolar mania. pediatric use information  for the treatment of pediatric patients with bipolar mania, 10 to 17 years of age, is approved for janssen pharmaceuticals corporation’s risperido

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg - risperidone orally disintegrating tablets, usp are indicated for the treatment of schizophrenia. efficacy was established in four short-term trials in adults, two short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . risperidone orally disintegrating tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in two short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] . risperidone orally disintegrating tablets adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperidone orally disintegrating tablets are indicated for the treatment of irritability associated with autistic disorder, including s